AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy

In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial! Abstracts: FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html Revumenib Late Breaking Abstract: https://ash.confex.com/ash/2023/webprogram/Paper192042.html JNJ617 Menin Inhibitor Data: https://ash.confex.com/ash/2023/webprogram/Paper172422.html SAVE Trial (Revumenib + PO Dec/ven): https://ash.confex.com/ash/2023/webprogram/Paper182337.html Dec/Ven vs. 3+7 Randomized Phase II: https://ash.confex.com/ash/2023/webprogram/Paper181347.html NCRI AML18 RCT: https://ash.confex.com/ash/2023/webprogram/Paper185956.html Impact of NPM1+/FLT3+/MRD in AML17 and AML19: https://ash.confex.com/ash/2023/webprogram/Paper179033.html CBF and NPM1 MRD: https://ash.confex.com/ash/2023/webprogram/Paper184848.html Persistent MRD by PCR but Flow Negativity in CBF AML (Mast Cell Madness): https://ash.confex.com/ash/2023/webprogram/Paper180275.html MORPHO More MRD Analysis: https://ash.confex.com/ash/2023/webprogram/Paper177929.html